Deal of The Day! Hurry Up, Grab the Special Discount - Save 25% - Ends In 00:00:00 Coupon code: SAVE25
Welcome to Pass4Success

- Free Preparation Discussions

SCDM CCDM Exam - Topic 3 Question 19 Discussion

If database auditing is used for data quality control during a study, which is the optimal timing of the audits?
D) Periodically throughout the study
A) Immediately following database lock
B) A week or two before database lock
C) After the first few cases have been entered

SCDM CCDM Exam - Topic 3 Question 19 Discussion

Actual exam question for SCDM's CCDM exam
Question #: 19
Topic #: 3
[All CCDM Questions]

If database auditing is used for data quality control during a study, which is the optimal timing of the audits?

Show Suggested Answer Hide Answer
Suggested Answer: D

Database audits are conducted to ensure ongoing data accuracy, completeness, and compliance throughout the lifecycle of a clinical trial. According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Quality Assurance and Control), quality audits are most effective when performed periodically during study conduct, rather than waiting until study completion.

Performing audits periodically allows early detection of data entry errors, protocol deviations, and system inconsistencies, thereby reducing the risk of large-scale data issues before database lock. This proactive approach aligns with risk-based quality management principles outlined in ICH E6(R2) and ensures corrective actions are implemented in real time.

Options A and B represent reactive quality control, which occurs too late to prevent data issues. Option C (after first few cases) provides initial validation but does not ensure continuous oversight.

Therefore, option D --- ''Periodically throughout the study'' --- represents the optimal and compliant timing for quality audits of the database.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 5.3 -- Ongoing Quality Control and Auditing

ICH E6(R2) GCP, Section 5.1.1 -- Quality Management System and Risk-Based Monitoring

FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.5 -- Data Review and Auditing Practices


Contribute your Thoughts:

0/2000 characters

Currently there are no comments in this discussion, be the first to comment!


Save Cancel